[Skip to Content]
[Skip to Content Landing]
December 1978

Gastrointestinal Therapeutic System for AcetazolamideEfficacy and Side Effects

Author Affiliations

From ALZA Research, Palo Alto, Calif. Dr Bayne is now with Cooper Laboratories, Mountain View, Calif.

Arch Ophthalmol. 1978;96(12):2219-2221. doi:10.1001/archopht.1978.03910060521010

• Acetazolamide has been formulated in a new gastrointestinal therapeutic system that delivers the drug at an essentially constant rate of 15 mg/hr (GITS 15/125). We compared the therapeutic effect, magnitude of plasma concentration fluctuations, and incidence of side effects produced by the GITS 15/125 with conventional 250-mg acetazolamide tablets on eight glaucomatous patients randomly assigned to a different regimen each week.

One or two GITS 15/125 twice a day (bid) were found as effective in reducing intraocular pressure as one 250-mg acetazolamide tablet. Plasma concentration fluctuations with the GITS 15/125 were decreased, compared with acetazolamide tablets, and, as a result, the incidence of drowsiness, tingling feet, tingling hands, and confusion was substantially reduced.